Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry

Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry

Abstract Background About 50% of all primary breast cancers show a low-level expression of HER2 (HER2-low), defined as immunohistochemically 1+ or 2+ and lack of HER2 gene amplification measured by in situ hybridization. This low HER2 expression is a promising new target for antibody–drug conjugates...

Full description

Bibliographic Details
Main Authors: Simon Peter Gampenrieder, Gabriel Rinnerthaler, Christoph Tinchon, Andreas Petzer, Marija Balic, Sonja Heibl, Clemens Schmitt, August Felix Zabernigg, Daniel Egle, Margit Sandholzer, Christian Fridolin Singer, Florian Roitner, Christopher Hager, Johannes Andel, Michael Hubalek, Michael Knauer, Richard Greil
Format: Article
Language:English
Published: BMC 2021-12-01
Series:Breast Cancer Research
Subjects:
Metastatic breast cancer
HER2-low
HER2-positive
HER2-negative
OS
PFS
Online Access:https://doi.org/10.1186/s13058-021-01492-x

Internet

https://doi.org/10.1186/s13058-021-01492-x

Similar Items